Bayer executives were keen to stress to Fierce this summer that the German pharma giant’s appetite for dealmaking hasn’t been curbed by a groupwide restructuring. Its latest cancer-focused collaboration suggests Bayer has indeed retained a taste for intriguing new modalities.

Four months after Chinese gene editing company YolTech Therapeutics took its cholesterol disease-focused candidate into the clinic, Salubris Pharmaceuticals has secured the local rights to the drug for 205 million Chinese yuan ($28.7 million).

Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.

The U.S. Department of Health and Human Services is sowing the seeds of advanced cancer treatment in the Prairie State. Through the Advanced Research Projects Agency for Health (ARPA-H) program, the department has granted engineering groups at the University of Illinois Urbana-Champaign two awards totaling about $54 million to develop new techniques for both studying and removing tumors.

Organ preservation and transport company Paragonix Technologies has agreed to be acquired through a $477 million deal offered by Getinge—which expects the international transplant market to continue growing by double digits and top $10 billion by 2033.

Arctoris, a contract research organization with a presence on both sides of the Atlantic, is putting together a new leadership team on the heels of a 2024 growth spurt.

For Lykos Therapeutics and the company’s would-be MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the hits just keep coming.

Actinogen Medical’s hopes—and stock price—have rebounded slightly from earlier this month, when the Australian biotech announced its cortisol blocker had failed to improve attention and memory in patients with cognitive dysfunction and major depressive disorder.

MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3 development.

Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off.